Prospective assessment of the role of five tumour markers in breast cancer.
Retrospective analysis previously identified significant elevation of five tumour markers, carcinoembryonic antigen (CEA), ferritin, orosomucoid. C-reactive protein and erythrocyte sedimentation rate (ESR), in patients with systemic breast cancer and showed that changes in each of these markers individually correlated significantly with therapeutic response. In this study we have prospectively tested these findings. None of the five markers was significantly elevated in primary breast cancer compared to normal control or benign breast disease groups. They therefore appear to have no role either in screening or in the differential diagnosis of breast cancer. There was a significant elevation of all five markers in patients with systemic breast cancer (P less than 0.0001: analysis of variance) but sequential changes in CEA and ESR only correlated significantly with the UICC-assessed response. Prospective confirmation of the correlation between changes in serum CEA and ESR provides the basis for using these markers in the assessment of response to therapy in patients with systemic breast cancer.
Robertson
J F
JF
Unit of Surgery, City Hospital, Nottingham, UK.
Pearson
D
D
Price
M R
MR
Selby
C
C
Pearson
J
J
Blamey
R W
RW
Howell
A
A
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D001799:Blood Sedimentation; D001943:Breast Neoplasms / Q000097:blood* / Q000628:therapy; D002097:C-Reactive Protein / Q000032:analysis; D002272:Carcinoembryonic Antigen / Q000097:blood; D005260:Female; D005293:Ferritins / Q000097:blood; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009961:Orosomucoid / Q000032:analysis; D011446:Prospective Studies
D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D009961:Orosomucoid; D002097:C-Reactive Protein; D005293:Ferritins